Research ExplorerPublicationsPrevention and Management of CMV Infections after Liver Tran...

Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers

Standard

Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers. / Engelmann, Cornelius; Sterneck, Martina; Weiss, Karl Heinz; Templin, Silke; Zopf, Steffen; Denk, Gerald; Eurich, Dennis; Pratschke, Johann; Weiss, Johannes; Braun, Felix; Welker, Martin-Walter; Zimmermann, Tim; Knipper, Petra; Nierhoff, Dirk; Lorf, Thomas; Jäckel, Elmar; Hau, Hans-Michael; Tsui, Tung Yu; Perrakis, Aristoteles; Schlitt, Hans-Jürgen; Herzer, Kerstin; Tacke, Frank.

In: J CLIN MED, Vol. 9, No. 8, 2352, 23.07.2020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Engelmann, C, Sterneck, M, Weiss, KH, Templin, S, Zopf, S, Denk, G, Eurich, D, Pratschke, J, Weiss, J, Braun, F, Welker, M-W, Zimmermann, T, Knipper, P, Nierhoff, D, Lorf, T, Jäckel, E, Hau, H-M, Tsui, TY, Perrakis, A, Schlitt, H-J, Herzer, K & Tacke, F 2020, 'Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers', J CLIN MED, vol. 9, no. 8, 2352. https://doi.org/10.3390/jcm9082352

APA

Engelmann, C., Sterneck, M., Weiss, K. H., Templin, S., Zopf, S., Denk, G., Eurich, D., Pratschke, J., Weiss, J., Braun, F., Welker, M-W., Zimmermann, T., Knipper, P., Nierhoff, D., Lorf, T., Jäckel, E., Hau, H-M., Tsui, T. Y., Perrakis, A., ... Tacke, F. (2020). Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers. J CLIN MED, 9(8), [2352]. https://doi.org/10.3390/jcm9082352

Vancouver

Engelmann C, Sterneck M, Weiss KH, Templin S, Zopf S, Denk G et al. Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers. J CLIN MED. 2020 Jul 23;9(8). 2352. https://doi.org/10.3390/jcm9082352

Bibtex

@article{a44d311984474e4c884edac87b9af672,
title = "Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers",
abstract = "Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives. Based on 20 out of 22 centers, we herein summarize the current approaches to CMV prevention and treatment in the context of liver transplantation in Germany. In 90% of centers, transient prophylaxis with ganciclovir or valganciclovir was standard of care in high-risk (donor CMV positive, recipient CMV naive) settings, while preemptive therapy (based on CMV viremia detected during (bi) weekly PCR testing for circulating CMV-DNA) was preferred in moderate- and low-risk settings. Duration of prophylaxis or intense surveillance was 3-6 months. In the case of CMV infection, immunosuppression was adapted. In most centers, antiviral treatment was initiated based on PCR results (median threshold value of 1000 copies/mL) with or without symptoms. Therefore, German transplant centers report similar approaches to the prevention and management of CMV infection in liver transplantation.",
author = "Cornelius Engelmann and Martina Sterneck and Weiss, {Karl Heinz} and Silke Templin and Steffen Zopf and Gerald Denk and Dennis Eurich and Johann Pratschke and Johannes Weiss and Felix Braun and Martin-Walter Welker and Tim Zimmermann and Petra Knipper and Dirk Nierhoff and Thomas Lorf and Elmar J{\"a}ckel and Hans-Michael Hau and Tsui, {Tung Yu} and Aristoteles Perrakis and Hans-J{\"u}rgen Schlitt and Kerstin Herzer and Frank Tacke",
year = "2020",
month = jul,
day = "23",
doi = "10.3390/jcm9082352",
language = "English",
volume = "9",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "8",

}

RIS

TY - JOUR

T1 - Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers

AU - Engelmann, Cornelius

AU - Sterneck, Martina

AU - Weiss, Karl Heinz

AU - Templin, Silke

AU - Zopf, Steffen

AU - Denk, Gerald

AU - Eurich, Dennis

AU - Pratschke, Johann

AU - Weiss, Johannes

AU - Braun, Felix

AU - Welker, Martin-Walter

AU - Zimmermann, Tim

AU - Knipper, Petra

AU - Nierhoff, Dirk

AU - Lorf, Thomas

AU - Jäckel, Elmar

AU - Hau, Hans-Michael

AU - Tsui, Tung Yu

AU - Perrakis, Aristoteles

AU - Schlitt, Hans-Jürgen

AU - Herzer, Kerstin

AU - Tacke, Frank

PY - 2020/7/23

Y1 - 2020/7/23

N2 - Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives. Based on 20 out of 22 centers, we herein summarize the current approaches to CMV prevention and treatment in the context of liver transplantation in Germany. In 90% of centers, transient prophylaxis with ganciclovir or valganciclovir was standard of care in high-risk (donor CMV positive, recipient CMV naive) settings, while preemptive therapy (based on CMV viremia detected during (bi) weekly PCR testing for circulating CMV-DNA) was preferred in moderate- and low-risk settings. Duration of prophylaxis or intense surveillance was 3-6 months. In the case of CMV infection, immunosuppression was adapted. In most centers, antiviral treatment was initiated based on PCR results (median threshold value of 1000 copies/mL) with or without symptoms. Therefore, German transplant centers report similar approaches to the prevention and management of CMV infection in liver transplantation.

AB - Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives. Based on 20 out of 22 centers, we herein summarize the current approaches to CMV prevention and treatment in the context of liver transplantation in Germany. In 90% of centers, transient prophylaxis with ganciclovir or valganciclovir was standard of care in high-risk (donor CMV positive, recipient CMV naive) settings, while preemptive therapy (based on CMV viremia detected during (bi) weekly PCR testing for circulating CMV-DNA) was preferred in moderate- and low-risk settings. Duration of prophylaxis or intense surveillance was 3-6 months. In the case of CMV infection, immunosuppression was adapted. In most centers, antiviral treatment was initiated based on PCR results (median threshold value of 1000 copies/mL) with or without symptoms. Therefore, German transplant centers report similar approaches to the prevention and management of CMV infection in liver transplantation.

U2 - 10.3390/jcm9082352

DO - 10.3390/jcm9082352

M3 - SCORING: Journal article

C2 - 32717978

VL - 9

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 8

M1 - 2352

ER -